Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.34
-0.20 (-2.34%)
Oct 22, 2024, 4:00 PM EDT - Market closed
Zevra Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Zevra Therapeutics stock have an average target of 21, with a low estimate of 17 and a high estimate of 25. The average target predicts an increase of 151.80% from the current stock price of 8.34.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ZVRA stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Oct 11, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Oct 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +139.81% | Sep 30, 2024 |
| JMP Securities | JMP Securities | Buy Initiates $17 | Buy | Initiates | $17 | +103.84% | Sep 24, 2024 |
| Maxim Group | Maxim Group | Strong Buy Maintains $18 → $25 | Strong Buy | Maintains | $18 → $25 | +199.76% | Sep 24, 2024 |
Financial Forecast
Revenue This Year
25.52M
from 27.46M
Decreased by -7.06%
Revenue Next Year
98.28M
from 25.52M
Increased by 285.10%
EPS This Year
-1.63
from -1.30
EPS Next Year
-0.60
from -1.63
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 38.2M | 127.2M | 219.8M | ||
| Avg | 25.5M | 98.3M | 182.2M | ||
| Low | 19.7M | 75.9M | 145.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 39.2% | 398.5% | 123.7% | ||
| Avg | -7.1% | 285.1% | 85.4% | ||
| Low | -28.2% | 197.2% | 47.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.56 | -0.08 | 0.95 | ||
| Avg | -1.63 | -0.60 | 0.26 | ||
| Low | -1.70 | -0.98 | -0.40 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.